Oral administration of IFN-α is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis

Journal of Autoimmunity

Volumn 9, Issue 1, 1996, Pages 11-20

  Brod, Staley A ^a   Khan, Mohammed ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

EAE; IFN ; IL 6; Oral IFN

Indexed keywords

ALPHA INTERFERON; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOREGULATION; LYMPH NODE CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0029985565     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0003     Document Type: Article

References (67)

1. Raine C.S., Stone S.H. 1977. Animal models for multiple sclerosis: Chronic experimental allergic encephalomyelitis in inbred guinea pigs. N.Y. State J. Med. 77: 1693-1696
2. Wisnewski H.M., Keith A.B. 1977. Chronic relapsing experimental allergic encelphalomyelitis: An experimental model of multiple sclerosis. Ann. Neurol. 1: 144-148
3. Feuer C., Prentice D.E., Cammusuli S. 1985. Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. J. Neuroimmunol. 10: 159-166
4. Abreu S.L. 1982. Suppression of experimental allergic encephalomyelitis by interferon. Immunol. Comm. 11: 1-7
5. Abreu S.L., Tondreau J., Levine S., Sowinski R. 1983. Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int. Archs. Allergy appl. Immun. 72: 30-33
6. 1. J. Immunol. 147: 1792-1796
7. Balkwill F.R. 1985. The regulatory role of interferons in the human immune response. In Interferons: Their impact in biology of medicine. Taylor-Papadimitriou, ed. Oxford Medical Publications, pp. 61-80
8. Brod S.A., Burns D.H. 1994. Suppression of relapsing experimental allergic encephalomyelitis in SJL/J mouse by oral administration of type 1 interferons. Neurology 44: 1144-1148
9. Brod S.A., Scott M., Burns D.H. Modification of acute experimental auto-immune encephalomyelitis in the Lewis rat by oral administration of type I interferons. J. Interferon Cyt. Res. 15: 115-122
10. Brod S.A., Khan M., Papolla M. 1995. Oral administration of human or murine IFN-α suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58: 61-69
11. IFNB MS Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 43: 655-661
12. IFNB MS Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 43: 662-667
13. Durelli L., Bongioanni M.R., Cavallo R., Ferraro B., Ferri B., Ferrio M.F., Bradac A., Riva G.B., Vai S., Geuna M., Bergnami L., Bergamasco B. 1994. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44: 406-413
14. Jacobs L., Cookfair D., Rudick R., Herndon R., Richert J., Salazar A., Fischer J., Granger C., Simon J., Goodkin D. and the MS Collaborative Group. 1994. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann. Neurol. 36(2): 259
15. IFNB MS Study Group and the University of British Columbia MS/MRI Analysis Group. 1995. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277-1285
16. Brown A.M., McFarlin D.E. 1981. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab. Invest. 45: 278-284
17. Miller S.D., Clatch R.J., Pevear D.C., Trotter J.L., Lipton H.L. 1987. Class II restricted T cell response in Theiler's murine encephalomyelitis virus induced demyelinating disease. J. Immunol. 138: 3776-3784
18. 2 biologically active on mouse cells. EMBO J. 6: 591-598
19. McInnes M., Chambers P.J., Cheetham B.F., Beilharz M.W., Tymms M.J. 1989. Structure function studies of interferons-α: amino acid substitutions at the conserved residue tyrosine 123 in human interferons-α. J. Interferon Res. 9: 305-314
20. Streuli M., Hall A., Boll W., Stewart W.E., Nagat S., Weissman C. 1981. Target cell specificity of two species of human interferon-α produced from Escherichia coli and of hybrid molecules derived from them. Proc. Natl. Acad. Sci. USA 78: 2848-2852
21. McDonald A.H., Swanborg R.H. 1988. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J. Immunol. 140: 1132-1138
22. 1b [Betaseron®] treatment of relapsing-remitting multiple sclerosis decreases CD3-mediated TNF-α and increases CD3-mediated IL-6 production ex vivo. Neurology in press
23. Mossmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. 1986. Two types of murine helper T cells. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2357
24. Kim J., Woods A., Becker-Dunn E., Bottomly K. 1985. Distinct functional phenotypes of cloned Ia-restricted helper T cells. J. Exp. Med. 162: 188-201
25. Cher D.J., Mossman T.R. 1987. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. J. Immunol. 138: 3688-3694
26. Boom W.H., Liano D., Abbas A.K. 1988. Heterogeneity of helper/inducer T lymphocytes II. Effects of interleukin-4 and interleukin-2 producing T cell clones on resting B cells. J. Exp. Med. 167: 1350-1363
27. Street N., Schumacher J.H., Fong T.A.T., Bass H., Fiorentino D.F., Leverach J.A., Mossman T.R. 1990. Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J. Immunol. 144: 1629-1637
28. Merrill J.E., Kono D.H., Clayton J., Ando D.G., Dinton H.R. 1992. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc. Natl. Acad. Sci. USA 89: 574-578
29. Brod S.A., Benjamin D., Hafler D.A. 1991. Restricted T cell expression of IL-2/IFN-γ mRNA in human inflammatory disease. J. Immunol. 147: 810-815
30. Yssel, H., Shanafelt M-C., Soderberg C., Schneider P.V., Anzola J., Peltz G. 1991. Borrelia burgdorferai activates a T helper type-1 like T cell subset in Lyme arthritis. J. Exp. Med. 174: 593-601
31. Haanan J., Malefijt R., Res P., Kraakman E.M., Otenhoff T.H., deVries R.R.P., Spits H. 1991. Selection of a human T helper type I-like T cell subset by Mycobacteria. J. Exp. Med. 174: 583-591
32. Liblau R.S., Singer S.M., McDevitt H.O. 1995. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16: 34-38
33. Mossman T.R., Moore K.W. 1991. The role of IL-10 in crossregulation of Th1 and Th2 responses. Immunol. Today 12: A49-53
34. Hirano T., Akira S., Taga T., Kishimoto T. 1990. Biological and clinical aspects of interleukin 6. Immunol. Today 11: 443-449
35. Wong G.G., Clark S.C. 1988. Multiple actions of interleukin 6 within a cytokine network. Immunol. Today 9: 137-139
36. 2/interleukin 6 is a co-stimulant for human T lymphocytes. J. Immunol. 141: 1556-1562
37. Brod S.A., Khan M., Bright J., Sriram S., Marshall G.D., Henninger E.M., Kerman R.H., Wolinsky J.S. Decreased CD3-mediated IFN-γ production in relapsing-remitting multiple sclerosis. Ann. Neurol. 37: 546-549
38. Stanton G., Hughes T., Heard H., Geordiades J., Whorton E. 1990. Modulation of a natural virus defense system by low concentrations of interferons at mucosal surfaces. J. Interferon Res. 10: (S-1) S99
39. Cummins J.M., Tompkins M.B., Olsen R.G., Tompkins W.A., Lewis M.G. 1988. Oral use of human alpha interferon in cats. J. Biol. Response Modifiers 7: 513-523
40. Lecce J.G., Cummins J.M., Richards A.B. 1990. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. J. Mol. Biotherapy 2: 211-216
41. Young A.S., Cummins J.M. 1990. The history of interferon and its use in animal therapy. E. African Med. J. 67(Suppl 2): SS31-63
42. Bocci V. 1990. Is interferon effective after oral administration? The state of the art. J. Biol. Reg. Homeostasis Agents 4: 81-83
43. Bocci V. 1990. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv. Drug Del. Rev. 4: 149-169
44. Bocci V. 1991. Absorption of cytokines via the oropharyngeal associated lymphoid tissues - Does an unorthodox route improve the therapeutic index of interferon? Clin. Pharmacokinet. 31: 411-417
45. Bocci V. 1985. Immunomodulators as local hormones: new insights regarding their clinical utilization. J. Biol. Res. Mod. 4: 340-352
46. Cantell K., Pyhala L. 1973. Circulating interferon in rabbits after administration by different routes. J. Gen. Virol. 20: 97-104
47. Hanley D., Wirowowska-Stewart M., Stewart W.E. 1979. Pharmacology of interferons. I. Pharmacologic distinctions between human leucocyte and fibroblast interferons. Int. J. Immunopharmacol. 1: 219-225
48. Stewart II W.E., Wirowowska-Stewart M. 1980. Characterization of human interferon types and subtypes. In Interferon. Properties and Clinical uses. A. Khan, N.O. Hill, G.L. Dorn, eds. L. Fikes press, Dallas. TX, pp. 111-120
49. 2 in rats. Int. J. Pharmaceutics 46: 199-202
50. Bocci V., Corradeschi F., Nicoletti C., Lencioni E. 1986. Enteric absorbtion of human interferon α and β in the rat. Int. J. Pharmaceutics 34: 111-114
51. Ruegg C.L., Strand M. 1990. Identification of a decapeptide region of human interferon α with antiproliferative activity and homology to an immunosuppressive sequence of the retroviral transmembrane protein P15E. J. Interferon Res. 10: 621-626
52. 4: identification of residues important for antiviral and antiproliferative activities. J. Interferon Res. 12: 43-48
53. Fleischmann W.R., Koren S., Fleischmann S.M. 1992. Oral administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201: 199-207
54. Gibson D.M., Cotler S., Spiegel H.E., Colburn W.A. 1985. Pharmacokinetics of recombinant leucocyte A interferon following various routes and modes of administration to the dog. J. Interferon Res. 5: 403-408
55. Willis R.J., Spiegel H.E., Soike K.F. 1984. Pharmacokinetics of recombinant leucocyte A interferon following IV infusion and bolus, IM, and PO administration to african green monkeys. J. Interferon Res. 4: 399-409
56. ser. J. Interferon Res. 12: 411-413
57. Bocci V. 1988. Roles of interferon produced in physiological conditions. A speculative review. Immunology 64: 1-9
58. Goldstein D., Sielaff K.M., Storer B.E., Brown R.R., Datta S.P., Witt P.J., Teitlebaum A.P., Smalley R.V., Borden E.C. 1989. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J. Natl. Cancer Inst. 81: 1061-1068
59. Blalock J.E., Baron S., Johnson H.M., Stanton G.J. 1982. Transmission of interferon-induced activities by cell to cell communication. Texas Reports on Biology and Medicine 41: 344-349
60. Kadish A.S., Tansey F.A., Yu G.S.M., Boyle A.T., Bloom B.R. 1980. Interferon as a mediator of human lymphocyte suppression. J. Exp. Med. 151: 637-650
61. Aune T.M., Pierce C.W. 1982. Activation of a suppressor T cell pathway by interferon. Proc. Nat. Acad. Sci. USA 79: 3808-3812
62. Schnapper H.W., Pierce C.W., Aune T.M. 1984. Identification and initial characterization of Con A and interferon-induced human suppressor factor: Evidence for a human equivalent of murine soluble immune response suppressor [SIRS]. J. Immunol 132: 2429-2435
63. Stobo J., Green I., Jackson L., Baron S. 1974. Identification of a subpopulation of mouse lymphoid cells required for interferon production after stimulation with mitogens. J. Immunol. 112: 1589-1593
64. Weil J., Epstein C., Epstein L.B., Sedmek J.J., Sabran J.L., Grossberg S.E. 1984. A unique set of polypeptides is induced by gamma interferon in addition to those induced in common with alpha and beta interferon. Nature. 301: 437-439
65. Pfeffer L.M., Donner D.D. 1990. The downregulation of IFN-α receptors in human lymphoblastoid cells: relation of cellular responsiveness to antiproliferative action of IFN-α. Cancer Research 50: 2654-2657
66. Uze G., Lutfalla G., Mogensen K.E. 1995. α and β interferons and their receptor and their friends and relations. J. Interferon Cyt. Res. 15: 3-26
67. ser. J. Int. Res. 9 Suppl 1: S51-60.